Financings in Brief: U.S. Surgical
This article was originally published in The Gray Sheet
U.S. Surgical: Files registration statement with the Securities and Exchange Commission related to the proposed sale of up to $200 mil. in debt securities, shares of preferred stock, common stock and the warrants to purchase them. The securities may be offered "from time to time, together or separately," the filing states. Proceeds will go toward general corporate purposes...
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.